Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
about
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medicationAssessment of the nevirapine safety signal using data from the national antiretroviral dispensing database: a retrospective study.Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretroviralsHepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania.Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.[Brazilian psychosocial and operational research vis-à-vis the UNGASS targets].Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes.Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina.Co-infections associated with human immunodeficiency virus type 1 in pregnant women from southern Brazil: high rate of intraepithelial cervical lesions.Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.Safety of nevirapine in pregnancyAdverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study
P2860
Q28749406-0F9023C4-D6D0-4362-923C-E48DB6F28899Q31046220-55B04A2D-D3BD-4FBC-A48A-207621099B7BQ33615251-BB9E922A-6DEC-447F-9C0A-09CC63A4C337Q35629349-539319B2-41E0-47E1-9A9A-926FEA32FB00Q36073787-3E18458D-E327-4AC8-862F-3DC1B56F4409Q37059321-7F9B3AB3-D49C-4C94-B8EE-76380564BE10Q37399082-0AE3988D-94B6-4C6B-AFE8-A103887C7DD9Q38452995-2590E71B-CC7A-43AC-9F8D-7149703D13E6Q42700015-60A5D98C-5004-46E9-B313-EFEF8D048BF6Q42869234-AD883622-A6BB-4F36-9FC6-77F586116AACQ45358987-79E48F89-38F5-4123-8203-26BAE4B9E532Q46524400-9374828A-5CD7-45AC-BFB5-40142A2E890AQ57180244-2B531B31-2EF4-4AAA-9274-B6B79BF63D4FQ59128516-F5314886-1A51-4406-9731-2D90F864957D
P2860
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
@en
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
@nl
type
label
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
@en
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
@nl
prefLabel
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
@en
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
@nl
P2093
P1476
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
@en
P2093
Esau Custódio João
Haroldo J Matos
Jacqueline A Menezes
Luisa Andrea T Salgado
Marcos M D'Ippolito
Maria Letícia S Cruz
P304
P356
10.1016/J.AJOG.2005.05.015
P407
P577
2006-01-01T00:00:00Z